Quick Takeaways:
- Zoetis has received US FDA approval for Convenia RTU for Dogs (cefovecin injectable suspension) to treat susceptible bacterial skin infections. A single injection administered by a veterinary professional provides up to 14 days of antibiotic treatment.
- The more concentrated formulation delivers the same dose in a smaller volume, making treatment practical for dogs of all sizes. It also helps owners avoid the daily challenge of administering oral antibiotics and reduces missed or irregular doses.
- Convenia RTU for Dogs is bioequivalent to Zoetis’ Convenia, approved in 2008. In a study, 86% of dogs needed just one cefovecin injection to resolve their infection. Better adherence may support treatment success and help reduce antibiotic resistance risks.
Why It Matters?
Zoetis strengthens its companion animal dermatology portfolio with Convenia RTU, offering a more concentrated formulation of an established long-acting injectable antibiotic. Reduced administration burden could improve adherence and differentiate it from oral antibiotics, while responsible antibiotic use and real-world treatment outcomes will shape veterinary adoption.
Source: Businesswire
